{"id":"W4200147408","doi":"10.1016/j.annonc.2021.10.018","title":"2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Atezolizumab; Oncology; Internal medicine; Adjuvant; Adjuvant chemotherapy; Chemotherapy; Stage (stratigraphy); Distributed File System; Cancer; Immunotherapy; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006440547,0.0003071995,0.001457532,0.0004576711,0.00002073067,0.000004707718,0.0002655487,0.0002090937,0.0007113037],"category_scores_gemma":[0.0001417762,0.0002852362,0.000309187,0.0007792923,0.0003695352,0.00009798296,0.0001370619,0.0002250775,0.000001592319],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001788846,"about_ca_system_score_gemma":0.001284362,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003438538,"about_ca_topic_score_gemma":0.008176238,"domain_scores_codex":[0.9968006,0.0003742842,0.001379654,0.0005150295,0.0004471024,0.0004833207],"domain_scores_gemma":[0.9978052,0.0001889455,0.0005548153,0.0007801404,0.000502773,0.000168092],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4155019,0.03038416,0.3494054,0.001190645,0.002273116,0.00416395,0.03474884,0.000006255219,0.05504978,0.0000247818,0.001193275,0.1060579],"study_design_scores_gemma":[0.1426182,0.0339377,0.710883,0.0008530169,0.0002669464,0.00002296528,0.06230433,0.00002283696,0.04344467,0.0000695162,0.005056535,0.0005202727],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909294,0.004694805,0.000002647721,0.001546835,0.0002817968,0.001105638,0.0004238223,0.00001116876,0.001003864],"genre_scores_gemma":[0.9975517,0.001533456,0.00004082521,0.0004536748,0.00004463554,0.00009130852,0.0000907034,0.00003984688,0.0001538041],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3614776,"threshold_uncertainty_score":0.99996,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04314062178960634,"score_gpt":0.3874494096085126,"score_spread":0.3443087878189063,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}